Letter from Milano: The challenges facing biotech from the coronavirus
Interviewee/Contributor
Pierluigi Paracchi
Organisation
Genenta Science SpA
Research Directory
What patients really want: involvement
Interviewee/ContributorPierre MeulienOrganisationInnovative Medicines InitiativeTime for action against antimicrobial resistance
Interviewee/ContributorLars Rebien SørensenOrganisationNovo Nordisk FoundationWhy we all go to JP Morgan year after year
Interviewee/ContributorEdwin MosesOrganisationAchilles Therapeutics LtdTechnology for direct cell reprogramming
Interviewee/ContributorJulian GoughOrganisationMogrify LtdComputers take the hand of medicine
Interviewee/ContributorWilliam EllingtonOrganisationMedNousA strategy for using AI in pharma R&D
Interviewee/ContributorEd CorbettOrganisationNovasecta LtdNovartis sets out its vision for pharma R&D
Interviewee/ContributorRobin DavisonOrganisationNew Science Global Healthcare FundBattle looms over immunotherapy combination
Interviewee/ContributorRobin DavisonOrganisationNew Science Global Healthcare FundWill CRISPR be safe enough for the clinic?
Interviewee/ContributorJonathan Moore